HhAntag691: all 78 studies that test it

Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.

• Adaptive Therapy of Vismodegib in Advanced Basal Cell CarcinomaRecruitingNCT05651828Early Phase 1
• Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell CarcinomaRecruitingNCT05561634Phase 2
• Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal CancerRecruitingNCT05538091Phase 2
• The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingNCT05159245Phase 2
• ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingNCT04341181Phase 2
• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasRecruitingNCT02523014Phase 2
• Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)Active, not recruitingNCT06357988Phase 2Results posted
• A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedNCT03498521Phase 2Results posted
• Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin CancerCompletedNCT02690948Phase 1/2Results posted
• VISmodegib for ORbital and Periocular Basal Cell CarcinomaCompletedNCT02436408Phase 4Results posted
• A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic TumorsCompletedNCT02366312Phase 2Results posted
• Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host DiseaseTerminatedNCT02337517Phase 2Results posted
• A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor BiopsyCompletedNCT02115828Early Phase 1Results posted
• My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsCompletedNCT02091141Phase 2Results posted
• Vismodegib in Basal Cell Carcinomas (BCC) ChemopreventionTerminatedNCT02067104Phase 2Results posted
• A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell CarcinomaTerminatedNCT01898598Phase 2Results posted
• A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic SyndromeTerminatedNCT01880437Phase 2Results posted
• Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell CarcinomaCompletedNCT01835626Phase 2Results posted
• A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell CarcinomasCompletedNCT01815840Phase 2Results posted
• Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine GliomaTerminatedNCT01774253Phase 2Results posted
• Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic SubtypesCompletedNCT01700049Phase 2Results posted
• Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)CompletedNCT01631331Early Phase 1Results posted
• Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell CarcinomasCompletedNCT01556009Phase 2Results posted
• A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic FunctionCompletedNCT01546519Phase 1Results posted
• Vismodegib for Treatment of Basal Cell CarcinomaCompletedNCT01543581Phase 2Results posted
• STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell CarcinomaCompletedNCT01367665Phase 2Results posted
• Vismodegib in Treating Patients With Advanced ChondrosarcomasActive, not recruitingNCT01267955Phase 2Results posted
• Vismodegib in Treating Younger Patients With Recurrent or Refractory MedulloblastomaCompletedNCT01239316Phase 2Results posted
• A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy ExistsCompletedNCT01209143Phase 1Results posted
• A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell CarcinomaCompletedNCT01201915Phase 2Results posted
• Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic CancerCompletedNCT01195415Phase 2Results posted
• Evaluation of Food Effect on Pharmacokinetics of VismodegibCompletedNCT01174264Phase 1/2Results posted
• Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate CancerTerminatedNCT01163084Phase 1/2Results posted
• Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01154452Phase 1/2Results posted
• Hedgehog Inhibitors for Metastatic Adenocarcinoma of the PancreasCompletedNCT01088815Phase 2Results posted
• Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic CancerCompletedNCT01064622Phase 2Results posted
• Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction CancerCompletedNCT00982592Phase 2Results posted
• GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by SurgeryCompletedNCT00980343Phase 2Results posted
• A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy ExistsCompletedNCT00968981Phase 1Results posted
• A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer StudyCompletedNCT00959647Phase 2Results posted
• To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)CompletedNCT00957229Phase 2Results posted
• Vismodegib in Treating Patients With Recurrent or Refractory MedulloblastomaCompletedNCT00939484Phase 2Results posted
• A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive StageCompletedNCT00887159Phase 2Results posted
• A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell CarcinomaCompletedNCT00833417Phase 2Results posted
• A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete RemissionCompletedNCT00739661Phase 2Results posted
• A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal CancerCompletedNCT00636610Phase 2Results posted
• GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT00607724Phase 1Results posted
• Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerSuspendedNCT06616623Phase 1
• SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Nivolumab With Vismodegib in Patients With Basal Cell Nevus SyndromeWithdrawnNCT03767439Phase 2
• Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1CompletedNCT03610022Phase 4
• NCT Neuro Master Match - N²M² (NOA-20)CompletedNCT03158389Phase 1/2
• Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO OverexpressionCompletedNCT03052478Phase 2
• Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell CarcinomaCompletedNCT03035188Phase 2
• To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell CarcinomaTerminatedNCT02956889Phase 2
• Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer PatientsStatus unknownNCT02694224Phase 2
• Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)CompletedNCT02667574Phase 2
• A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary FibrosisCompletedNCT02648048Phase 1
• Photodynamic Therapy and Vismodegib for Multiple Basal Cell CarcinomasCompletedNCT02639117Phase 1
• A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)CompletedNCT02593760Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)WithdrawnNCT02168530Phase 2
• Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic LeukemiaTerminatedNCT01944943Phase 2
• A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed MedulloblastomaActive, not recruitingNCT01878617Phase 2
• A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of VismodegibCompletedNCT01772290Phase 1
• Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic CancerStatus unknownNCT01713218Early Phase 1
• Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog PathwayTerminatedNCT01601184Phase 1/2
• Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By SurgeryCompletedNCT01537107Phase 1
• Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple MyelomaCompletedNCT01330173Phase 1
• A Study to Investigate the Effect of GDC-0449 on the QT/QTc Interval in Healthy Female SubjectsCompletedNCT01173536Phase 1
• Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)TerminatedNCT01096732Phase 2
• RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By SurgeryTerminatedNCT01071564Phase 1
• A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing PotentialCompletedNCT00991718Phase 1
• GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by SurgeryActive, not recruitingNCT00878163Phase 1
• GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous TreatmentCompletedNCT00822458Phase 1

← HhAntag691 overview